
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is experiencing a positive outlook driven by robust sales growth attributed to higher demand and market share gains, particularly with Biktarvy, which commands 52% of the U.S. market share and has consistently increased since its launch. The company's projections indicate a notable increase in sales, with HIV growth guidance raised to +5% year-over-year, despite anticipated headwinds, reflecting successful lifecycle management strategies. Furthermore, expansion in the oncology sector, including the promising early programs in inflammation and immunology (I&I), positions Gilead to capture additional market share and boost overall revenue in the coming years.
Bears say
Gilead Sciences faces a negative outlook due to declining revenues in key therapeutic areas, with Veklury reporting a significant 60% year-over-year decrease to $277 million, falling short of market expectations and prompting a downward revision in revenue guidance for fiscal year 2025. Additionally, sales from Trodelvy have experienced a slight quarter-over-quarter decline to $357 million, compounded by forecasts predicting a 10% year-over-year drop in revenue from cell therapy in 2025, underscoring competitive challenges in the oncology segment. The overall performance in cell therapies, down 11% year-over-year, further highlights the company's struggles amid increasing competition, contributing to a cautious sentiment regarding Gilead's financial prospects.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares